GeoVax Labs, Inc. (NASDAQ:GOVX) Given Consensus Recommendation of “Buy” by Brokerages

GeoVax Labs, Inc. (NASDAQ:GOVX) has received an average recommendation of “Buy” from the six analysts that are currently covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $13.25.

GOVX has been the topic of a number of research analyst reports. Alliance Global Partners initiated coverage on shares of GeoVax Labs in a research note on Monday, November 11th. They issued a “buy” rating and a $15.00 price target on the stock. Noble Financial boosted their price target on shares of GeoVax Labs from $6.00 to $10.00 and gave the company an “outperform” rating in a research note on Monday, August 19th. HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of GeoVax Labs in a research note on Friday. Finally, EF Hutton Acquisition Co. I raised shares of GeoVax Labs to a “strong-buy” rating in a research note on Tuesday, July 23rd.

GeoVax Labs Stock Down 6.9 %

Shares of GOVX stock opened at $2.43 on Monday. The firm’s 50-day moving average is $2.37 and its two-hundred day moving average is $2.62. GeoVax Labs has a 12 month low of $1.09 and a 12 month high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.91) EPS for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.38. The firm had revenue of $2.79 million for the quarter, compared to analysts’ expectations of $1.84 million. During the same period last year, the firm earned ($4.80) earnings per share. As a group, equities analysts predict that GeoVax Labs will post -4.49 EPS for the current fiscal year.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.